$A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer$

A randomized study to evaluate the safety and efficacy of two dosages of lenvatinib – 18 and 24 mg – in patients with radioiodrefract differentiated thyroid cancer

Введение. Ленватиниб является мультикиназным ингибитором, одобренным для лечения радиойодрефрактерного дифференцированного рака щитовидной железы (РЙР-ДРЩЖ) в стартовой дозе 24 мг / день. Данное двойное слепое исследование было проведено с целью определения, будет ли использование ленватиниба в стар...

Full description

Bibliographic Details
Main Authors:	M. S. Brose, Yu. Panaseykin, B. Konda, C. de la Fouchardiere, B. G.M. Hughes, A. G. Gianoukakis, Y. J. Park, I. Romanov, M. K. Krzyzanowska, S. Leboulleux, T. A. Binder, C. Dutcus, R. Xie, M. H. Taylor
Format:	Article
Language:	Russian
Published:	ABV-press 2022-04-01
Series:	Опухоли головы и шеи
Subjects:	ленватиниб радиойодрефрактерный дифференцированный рак щитовидной железы ингибитор тирозинкиназ стартовая доза
Online Access:	https://ogsh.abvpress.ru/jour/article/view/740

Similar Items

Personalized therapy with lenvatinib for progressive radioiodine refractory differentiated thyroid cancer in routine clinical practice
by: P. O. Rumyantsev, et al.
Published: (2021-11-01)

Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
by: A. G. Gianoukakis, et al.
Published: (2018-11-01)

Effect of age on the efficacy and safety of lenvatinib in radioiodine-refractory differentiated thyroid cancer in the phase III SELECT Trial
by: M. S. Brose, et al.
Published: (2018-07-01)

New-generation mutitargeted tyrosine kinase inhibitors in the treatment of radioactive iodine-refractory differentiated thyroid cancer
by: A. M. Mudunov
Published: (2015-06-01)

Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer
by: M. E. Cabanillas, et al.
Published: (2020-02-01)

Clinical experience in using lenvatinib in patients with progressive, radioactive iodine-refractory differentiated thyroid cancer
by: P. A. Isaev, et al.
Published: (2016-06-01)

Влияние прерывания терапии ленватинибом на общую эффективность лечения у пациентов с радиойодрезистентным дифференцированным раком щитовидной железы в исследовании III фазы
by: M. Tahara, et al.
Published: (2019-04-01)

Survival analysis of patients with advanced metastatic differentiated thyroid cancer
by: E. V. Borodavina, et al.
Published: (2022-08-01)

Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma
by: K. V. Menshikov, et al.
Published: (2023-01-01)

LENVATINIB IN TREATMENT OF RADIOACTIVE IODINE-REFRACTORY WELL-DIFFERENTIATED THYROID CARCINOMA
by: I. S. Romanov, et al.
Published: (2017-06-01)

Efficacy and tolerability of lenvatinib in patients with radioiodine-refractory differentiated thyroid cancer: results of a multicenter observational study in the Russian Federation
by: E. V. Borodavina, et al.
Published: (2020-04-01)

Experience in the use of targeted therapy in patients with radio-resistant forms of thyroid cancer in the Chelyabinsk Regional Clinical Center of Oncology and Nuclear Medicine
by: E. B. Vasil’eva, et al.
Published: (2018-04-01)

Diagnostic score of malignancy risk in the people having a node in thyroid gland (Petrov Thyroid Cancer Score, PTCS)
by: A. M. Belyaev, et al.
Published: (2018-04-01)

Analysis of treatment outcomes in patients with progressive locally advanced non-resectable and disseminated medullary thyroid cancer receiving vandetanib outside of clinical trials (Russian experience)
by: I. S. Romanov, et al.
Published: (2020-07-01)

Efficacy of vandetanib in the treatment of medullary thyroid cancer: literature review and case report
by: А. М. Mudunov, et al.
Published: (2019-10-01)

Experience of Hepatocellular Cancer Therapy with Multikinase Inhibitors in the Republic of Bashkortostan
by: Sh. Kh. Gantsev, et al.
Published: (2020-11-01)

Historical aspects and modern concepts in the treatment of patients with differentiated thyroid cancer, refractory to radioactive iodine therapy
by: E. V. Borodavina, et al.
Published: (2022-02-01)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021-01-01)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
by: S. K. Zyryanov, et al.
Published: (2018-05-01)

Value of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in staging of patients with differentiated thyroid cancer after thyroidectomy during the first course of radioiodine therapy
by: T. M. Geliashvili, et al.
Published: (2021-01-01)

ORGANIZING THE MUSIC CLASSES IN STARTING SCHOOLS
by: N. G. Tagiltseva
Published: (2015-03-01)

On the role of autophagy in the progression of differentiated thyroid cancer (literature review)
by: K. A. Garipov, et al.
Published: (2022-01-01)

COMBINATION OF LENVATINIB AND PEMBROLISUMAB IN THE TREATMENT OF ADVANCED ENDOMETRIAL CANCER: A CASE REPORT
by: O. N. Churuksaeva, et al.
Published: (2021-03-01)

<sup>18</sup>F-fluorodeoxyglucose positron emission tomography combined with computed tomography for the prediction of radioiodine therapy response in patients with metastatic differentiated thyroid cancer
by: T. M. Geliashvili, et al.
Published: (2020-02-01)

Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
by: Matthew H. Taylor, et al.
Published: (2023-02-01)

The use of 18F-fluorodeoxyglucose positron emission tomography combined with computed tomography in patients with differentiated thyroid cancer after initial treatment
by: T. M. Geliashvili, et al.
Published: (2017-04-01)

Tall-cell variant of papillary thyroid carcinoma: literature review and case reports
by: E. V. Borodavina, et al.
Published: (2020-11-01)

ROLE OF HIGH-FIELD MAGNETIC RESONANCE IMAGING IN DETECTION OF NODULAR LESIONS OF THE THYROID
by: E. E. Bober, et al.
Published: (2016-02-01)

DIAGNOSTIC IMAGING MODALITIES FOR DETECTION OF LUNG METASTASES IN PATIENTS WITH DIFFRENTIATED THYROID CANCER
by: Т. М. Geliashvili, et al.
Published: (2016-02-01)

ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES
by: Z. M. Safiullina, et al.
Published: (2015-09-01)

USE OF REMICADE® IN PATIENTS WITH CHRONIC TOPHACEOUS GOUT: THEORETICAL RATIONALE AND ASSESSMENT OFOWN EXPERIENCE
by: M S Eliseyev, et al.
Published: (2009-06-01)

CHOICE OF THE INITIAL TREATMENT FOR MILD TO MODERATE ARTERIAL HYPERTENSION IN MOSCOW PRIMARY PRACTICE
by: S. V. Gatsura, et al.
Published: (2015-09-01)

RESULTS OF CLINICAL TRIALS OF MEDICAL TREA TMENT OF RENAL CELL CARCINOMA IN 2014–2015
by: A. M. Popov, et al.
Published: (2016-01-01)

THE SIGNIFICANCE OF THE METHOD OF ULTRASONIC RESEARCH OF A THYROID GLAND WITH CONTRAST ENHANCEMENT IN THE DIFFERENTIAL DIAGNOSIS OF FOCAL NODULAR FORMATIONS
by: D. A. Rakitina, et al.
Published: (2017-06-01)

FUNCTIONAL DISORDERS IN THE SPINE DEFORMATIONS AND METHODS FOR THEIR CORRECTION
by: G. S. Lupandina-Bolotova, et al.
Published: (2015-04-01)

Сорафениб в последовательной терапии метастатического рака почки
Published: (2019-09-01)

CLINICAL CASE OF TREATMENT OF A PATIENT WITH CHRONIC MYELOID LEUKEMIA WITH A MUTATION BCR-ABL Y253H AND COMORBIDITIES
by: G. Sh. Safuanova, et al.
Published: (2019-05-01)

Resolution of the expert council on the topic “Clinical practice of drug therapy of thyroid cancer”
by: article Editorial
Published: (2022-08-01)

A new algorithm of treatment choice in primary open-angle glaucoma
by: A. A. Antonov, et al.
Published: (2022-01-01)

Will the BEAUTIFUL Study results change our views on heart rate control?
by: Yu. M. Lopatin
Published: (2008-12-01)